1-ethyl-4-octyloxybenzene | 1379023-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-ethyl-4-octyloxybenzene
• 英文别名: 1-Ethyl-4-octoxybenzene
• CAS: 1379023-18-3
• 化学式: C₁₆H₂₆O
• 分子量: 234.382
• InChiKey: UMZHQRSWWXJOJW-UHFFFAOYSA-N

物化性质

• 沸点：
  320.8±11.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2-dimethyl-5-(1-(4-(octyloxy)phenyl)ethyl)-1,3-dioxane-4,6-dione 在 甲醇 、 palladium 10% on activated carbon 、 氢气 作用下， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 生成 1-ethyl-4-octyloxybenzene
  参考文献：
  名称：

  未受约束的碳-碳 σ 键的氢解：立体选择性进入苄基三级中心

  摘要：

  描述了通过 Pd 催化还原裂解无应变的碳-碳 sigma 键对 sp(3)-杂化碳中心的修饰。从带有全碳苄基季中心的苄基 Meldrum 酸的氢解中，Meldrum 酸和被叔苄基立体中心取代的芳烃以良好到极好的收率获得。机理研究表明，对映体富集的苄基四元中心的还原裂解继续进行构型反转，支持“松散”的 S(N)2 通路。

  DOI：

  10.1021/ja9076815

文献信息

• [PSI[CH2NH]PG4] glycopeptide antibiotic analogs
  申请人：Boger L. Dale

  公开号：US20070173438A1

  公开（公告）日：2007-07-26

  [ψ[CH 2 NH]PG 4 ] glycopeptide antibiotic analogs are reengineered forms of glycopeptides that exhibit antimicrobial activity against both wild type and glycopeptide antibiotic resistant strains of microorganisms. For example, [ψ[CH 2 NH]Tpg 4 ] vancomycin aglycon is a reengineered form of vancomycin that exhibits antimicrobial activity (MIC=31 μg/mL) against both wild type and VanA resistant organism ( E. faecalis BM4166). The VanA resistant organism achieves its resistance, upon glycopeptide antibiotic challenge, by remodeling its D-Ala-D-Ala peptidoglycan cell wall precursor to D-Ala-D-Lac. [ψ[CH 2 NH]PG 4 ] glycopeptide antibiotic analogs have an altered glycopeptide backbone wherein the carbonyl of the fourth amino acid residue of the glycopeptide backbone has been replaced with a methylene. This alteration of the glycopeptide backbone imparts dual binding affinities for both D-Ala-D-Ala and D-Ala-D-Lac and dual antimicrobial activities for both wild type and resistant strains. For example, [ψ[CH 2 NH]Tpg 4 ]vancomycin aglycon displays a antimicrobial potency that reflects its altered binding characteristics.

  [ψ[CH2NH]PG4] 糖肽抗生素类似物是糖肽的重新设计形式，对野生型和糖肽抗生素耐药菌株都表现出抗微生物活性。例如，[ψ[CH2NH]TPG4] 万古霉素裸核是万古霉素的重新设计形式，对野生型和VanA耐药菌株（E. faecalisBM4166）都表现出抗微生物活性（MIC=31 μg/mL）。VanA耐药菌株通过重塑其D-Ala-D-Ala肽聚糖细胞壁前体为D-Ala-D-Lac，在糖肽抗生素挑战下获得其抗性。[ψ[CH2NH]PG4] 糖肽抗生素类似物具有改变的糖肽骨架，其中糖肽骨架的第四个氨基酸残基的羰基被亚甲基取代。这种糖肽骨架的改变赋予了对D-Ala-D-Ala和D-Ala-D-Lac的双重结合亲和力，以及对野生型和耐药菌株的双重抗微生物活性。例如，[ψ[CH2NH]TPG4] 万古霉素裸核显示出反映其改变的结合特性的抗微生物效力。
• Facile Hydrogenolysis of C(<i>sp</i>³)-C(<i>sp</i>³) σ Bonds
  作者：Eric Fillion、Eric Beaton、Yen Nguyen、Ashraf Wilsily、Ganna Bondarenko、Jérôme Jacq

  DOI：10.1002/adsc.201600535

  日期：2016.11.3

  reductive dealkylation reaction is explored and the limitations with respect to steric and electronic factors are determined. A mechanistic analysis of the reaction is described that consisted of deuterium labelling experiments and hydrogenolysis of enantioenriched derivatives. The investigation shows that the C(sp3)–C(sp3) σ bond‐cleaving events occur through a hybrid SN1/SN2 mechanism, in which the palladium

  通过钯催化的C（sp 3）–C（sp 3）氢解对苄基的季碳，叔碳和仲碳中心进行修饰）呈现σ键。当在温和的氢解条件下（含钯碳和氢气的大气压）处理带有季苄基中心的苄基麦德鲁姆的酸衍生物时，就可以很好地获得高收率的芳族化合物，这些芳族化合物被叔苄基中心和麦德鲁姆酸所取代。类似地，含有叔或仲苄基中心的底物分别产生被仲苄基中心或甲苯衍生物取代的芳族化合物。此外，该策略用于二芳基甲烷的高产率合成。探索了还原性脱烷基反应的范围，并确定了对空间和电子因素的限制。描述了该反应的机理分析，该分析由氘标记实验和对映体富集的衍生物的氢解组成。调查显示，C（sp 3）–C（sp 3）σ键断裂事件是通过混合的S N 1 / S N 2机理发生的，其中钯中心置换了一个基于碳的离去基团，即Meldrum酸，其构型反转，随后通过还原消除钯来提供CH键。
• Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof
  申请人：Paris Daniel

  公开号：US20080058330A1

  公开（公告）日：2008-03-06

  Provided are compounds which can be used in combination for treating diseases associated with a condition associated with cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which in combination can decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of the compounds.

  提供了一些化合物，可以组合使用来治疗与阿尔茨海默病淀粉样蛋白相关的疾病，如阿尔茨海默病。还提供了一种方法，通过给予治疗有效量的化合物组合来减少β-淀粉样蛋白的产生和细胞中的电容性钙离子进入，从而治疗或降低发生β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau异常过度磷酸化）和与阿尔茨海默病淀粉样蛋白相关的微胶质病变。此外，还提供了一种方法，通过给予诊断有效量的化合物来诊断动物或人类中与阿尔茨海默病淀粉样蛋白相关的疾病。
• Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
  申请人：Mullan J. Michael

  公开号：US20070037855A1

  公开（公告）日：2007-02-15

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供的化合物可用于治疗与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病，例如阿尔茨海默病。还提供了筛选此类化合物的方法，通过测量细胞中的电容性钙离子进入，其中细胞可以选择性地过度表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau的异常高磷酸化）和与阿尔茨海默淀粉样蛋白在大脑中积累有关的微胶质细胞增生的方法。此外，还提供了通过给动物或人类施用诊断有效量的抑制电容性钙离子进入细胞的化合物来诊断与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病的方法。
• Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds
  申请人：Mullan Michael J.

  公开号：US20100215735A1

  公开（公告）日：2010-08-26

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供了一些化合物，可用于治疗与阿尔茨海默氏淀粉样物质在大脑中积累有关的疾病，如阿尔茨海默病。还提供了筛选这些化合物的方法，通过测量在细胞中的电容性钙离子进入，这些细胞可以选择性地过表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低发生β-淀粉样物质产生、β-淀粉样物质沉积、β-淀粉样物质神经毒性（包括tau异常过磷酸化）和与阿尔茨海默氏淀粉样物质在大脑中积累有关的小胶质细胞增生的风险的方法，这些化合物可以减少β-淀粉样物质产生和细胞中的电容性钙离子进入。此外，还提供了通过给动物或人体内给予诊断有效量的化合物来诊断与阿尔茨海默氏淀粉样物质在大脑中积累有关的疾病的方法，这些化合物可以抑制细胞中的电容性钙离子进入。